First Eagle Investment Management
BIO icon

First Eagle Investment Management’s Bio-Rad Laboratories Class A BIO Stock Holding History

First Eagle Investment Management’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$765M Buy
2,606,219
+3,447
+0.1% +$978K 1.26% 30
2026
Q1 		$726M Buy
2,602,772
+32,299
+1% +$9.3M 1.23% 33
2025
Q4 		$779M Buy
2,570,473
+50,154
+2% +$15.7M 1.37% 32
2025
Q3 		$707M Buy
2,520,319
+3,006
+0.1% +$818K 1.29% 30
2025
Q2 		$607M Buy
2,517,313
+951,123
+61% +$225M 1.19% 35
2025
Q1 		$381M Buy
1,566,190
+852,685
+120% +$257M 0.8% 44
2024
Q4 		$234M Buy
713,505
+505
+0.1% +$171K 0.52% 55
2024
Q3 		$239M Buy
713,000
+76,725
+12% +$24.4M 0.49% 54
2024
Q2 		$174M Buy
636,275
+634,311
+32,297% +$184M 0.39% 59
2024
Q1 		$679K Buy
1,964
+1,485
+310% +$488K ﹤0.01% 357
2023
Q4 		$155K Buy
479
+21
+5% +$6.58K ﹤0.01% 394
2023
Q3 		$164K Buy
458
+267
+140% +$103K ﹤0.01% 385
2023
Q2 		$72.4K Buy
+191
New +$77.7K ﹤0.01% 381

Other funds holding BIO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

First Eagle Investment Management's BIO Position: Q2 2026 in Review

First Eagle Investment Management increased its Bio-Rad Laboratories Class A (BIO) stake by 0.13% in Q2 2026, buying an estimated $978K and bringing the position to 2,606,219 shares worth $765M. The position accounts for 1.26% of the portfolio, ranked #30.

First Eagle Investment Management first reported a position in BIO in Q2 2023 and has held it in 13 quarters since. The position peaked at $779M in Q4 2025. 397 funds tracked by Wall St. Rank hold BIO as of Q2 2026.

  • First Eagle Investment Management held 2,606,219 shares of Bio-Rad Laboratories Class A worth $765M as of Q2 2026.
  • First Eagle Investment Management bought 3,447 Bio-Rad Laboratories Class A shares in Q2 2026, an estimated $978K.
  • Bio-Rad Laboratories Class A made up 1.26% of First Eagle Investment Management's portfolio in Q2 2026, its #30 holding.
  • First Eagle Investment Management first reported a position in Bio-Rad Laboratories Class A in Q2 2023 and has held it in 13 quarters since.
  • First Eagle Investment Management's Bio-Rad Laboratories Class A position peaked at $779M in Q4 2025.
  • 397 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2026.

Based on First Eagle Investment Management's 13F filing for Q2 2026, filed 5 Aug 2026.